Legal & General Group
NBIX icon

Legal & General Group’s Neurocrine Biosciences NBIX Stock Holding History

Legal & General Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.1M Buy
380,589
+49,983
+15% +$6.63M 0.01% 626
2025
Q4 		$46.9M Sell
330,606
-69,564
-17% -$10.1M 0.01% 637
2025
Q3 		$56.2M Buy
400,170
+744
+0.2% +$101K 0.01% 602
2025
Q2 		$50.2M Buy
399,426
+16,499
+4% +$1.89M 0.01% 615
2025
Q1 		$42.4M Buy
382,927
+37,237
+11% +$4.72M 0.01% 645
2024
Q4 		$47.2M Sell
345,690
-44,895
-11% -$5.55M 0.01% 627
2024
Q3 		$45M Sell
390,585
-11,914
-3% -$1.63M 0.01% 654
2024
Q2 		$55.4M Sell
402,499
-117
-0% -$16K 0.02% 603
2024
Q1 		$55.5M Sell
402,616
-38,891
-9% -$5.31M 0.02% 610
2023
Q4 		$58.2M Sell
441,507
-6,641
-1% -$764K 0.02% 602
2023
Q3 		$50.4M Sell
448,148
-9,584
-2% -$1.01M 0.02% 622
2023
Q2 		$43.2M Sell
457,732
-36,186
-7% -$3.54M 0.01% 667
2023
Q1 		$50M Buy
493,918
+2,696
+0.5% +$281K 0.02% 627
2022
Q4 		$58.7M Sell
491,222
-5,816
-1% -$681K 0.02% 583
2022
Q3 		$52.8M Sell
497,038
-9,672
-2% -$981K 0.02% 612
2022
Q2 		$49.4M Buy
506,710
+33,279
+7% +$3.07M 0.02% 638
2022
Q1 		$44.4M Buy
473,431
+26,254
+6% +$2.23M 0.01% 692
2021
Q4 		$38.1M Sell
447,177
-2,944
-0.7% -$271K 0.01% 738
2021
Q3 		$43.2M Buy
450,121
+1,625
+0.4% +$153K 0.01% 707
2021
Q2 		$43.6M Buy
448,496
+42,915
+11% +$4.11M 0.01% 712
2021
Q1 		$39.4M Buy
405,581
+66,890
+20% +$7.01M 0.01% 717
2020
Q4 		$32.5M Sell
338,691
-29,488
-8% -$2.85M 0.01% 730
2020
Q3 		$35.4M Sell
368,179
-9,306
-2% -$1.08M 0.02% 680
2020
Q2 		$46.1M Buy
377,485
+94,980
+34% +$10.5M 0.02% 587
2020
Q1 		$24.5M Buy
282,505
+21,196
+8% +$2.07M 0.01% 686
2019
Q4 		$28.1M Buy
261,309
+197,544
+310% +$20.7M 0.01% 732
2019
Q3 		$5.75M Buy
63,765
+11,467
+22% +$1.07M ﹤0.01% 1233
2019
Q2 		$4.42M Buy
52,298
+718
+1% +$59K ﹤0.01% 1336
2019
Q1 		$4.54M Sell
51,580
-8,987
-15% -$751K ﹤0.01% 1244
2018
Q4 		$4.33M Sell
60,567
-4,598
-7% -$441K ﹤0.01% 1136
2018
Q3 		$8.01M Buy
65,165
+25,365
+64% +$2.88M 0.01% 949
2018
Q2 		$3.91M Sell
39,800
-5,011
-11% -$449K ﹤0.01% 1280
2018
Q1 		$3.72M Sell
44,811
-561
-1% -$47.4K ﹤0.01% 1265
2017
Q4 		$3.52M Buy
45,372
+8,875
+24% +$605K ﹤0.01% 1294
2017
Q3 		$2.24M Buy
36,497
+4,638
+15% +$245K ﹤0.01% 1525
2017
Q2 		$1.47M Buy
31,859
+2,554
+9% +$124K ﹤0.01% 1684
2017
Q1 		$1.27M Buy
29,305
+19,955
+213% +$855K ﹤0.01% 1710
2016
Q4 		$362K Buy
9,350
+1,136
+14% +$51.4K ﹤0.01% 2063
2016
Q3 		$415K Buy
8,214
+1,215
+17% +$60.5K ﹤0.01% 1792
2016
Q2 		$318K Sell
6,999
-12,289
-64% -$566K ﹤0.01% 1584
2016
Q1 		$759K Buy
19,288
+1,862
+11% +$73.9K ﹤0.01% 1205
2015
Q4 		$980K Buy
17,426
+958
+6% +$48.7K ﹤0.01% 1160
2015
Q3 		$628K Buy
16,468
+688
+4% +$33.3K ﹤0.01% 1236
2015
Q2 		$750K Buy
15,780
+1,926
+14% +$81.7K ﹤0.01% 1214
2015
Q1 		$567K Buy
13,854
+2,418
+21% +$86.5K ﹤0.01% 1254
2014
Q4 		$258K Hold
11,436
– – ﹤0.01% 1455
2014
Q3 		$178K Buy
+11,436
New +$171K ﹤0.01% 1568

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legal & General Group's NBIX Position: Q1 2026 in Review

Legal & General Group increased its Neurocrine Biosciences (NBIX) stake by 15% in Q1 2026, buying an estimated $6.63M and bringing the position to 380,589 shares worth $50.1M. The position accounts for 0.01% of the portfolio, ranked #626.

Legal & General Group first reported a position in NBIX in Q3 2014 and has held it in 47 quarters since. The position peaked at $58.7M in Q4 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Legal & General Group held 380,589 shares of Neurocrine Biosciences worth $50.1M as of Q1 2026.
  • Legal & General Group bought 49,983 Neurocrine Biosciences shares in Q1 2026, an estimated $6.63M.
  • Neurocrine Biosciences made up 0.01% of Legal & General Group's portfolio in Q1 2026, its #626 holding.
  • Legal & General Group first reported a position in Neurocrine Biosciences in Q3 2014 and has held it in 47 quarters since.
  • Legal & General Group's Neurocrine Biosciences position peaked at $58.7M in Q4 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.